Controversies in intrathecal drug delivery for cancer pain. Review uri icon

Overview

abstract

  • Pain and suffering related to cancer are challenging issues that continue to deserve consideration for treatment optimization. Advances in analgesic management and control of the underlying cancer have improved symptom management, yet many patients still suffer from uncontrolled pain. Intrathecal drug delivery has an established role in the management of refractory cancer pain, but there are significant knowledge gaps in our understanding and application of this therapy. This review addresses several areas of controversy, including the importance of intrathecal catheter tip location, the necessity of an intrathecal trial and the role of intrathecal ziconotide and local anesthetics. In each area, the evidence is discussed, with an emphasis on presenting practical clinical guidance and highlighting deficiencies in our knowledge that are worthy of future investigation.

publication date

  • August 17, 2022

Research

keywords

  • Cancer Pain
  • Neoplasms
  • Pain, Intractable

Identity

Scopus Document Identifier

  • 85137255615

Digital Object Identifier (DOI)

  • 10.1136/rapm-2022-103770

PubMed ID

  • 35977779

Additional Document Info

volume

  • 48

issue

  • 6